Skip to main content

Table 2 Poly Q sequence patterns and AIB1 amplification level in MCF7 and its variants

From: AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines

Cell linea amplification Sequence patterns Pattern (Q)n Frequency
MCF-7 22.3 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 7/7
MCF-7 P19 18.7 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 7/9
   (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 1/9
   (CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 3 28 1/9
MCF-7 P72 22.8 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 5/7
   (CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/7
   (CAG)3CAA(CAG)7(CAACAG)3(CAACAGCAG)2CAA 5 24 1/7
LCC1 13.5 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 7/9
   (CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/9
   (CAG)3CAA(CAG)14(CAACAG)2(CAACAGCAG)2CAA 6 29 1/9
LCC2 14.6 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 4/5
   CAG(CAACAG)3(CAACAGCAG)2CAA 7 14 1/5
LCC9 15.6 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 7/8
   (CAG)3CAA(CAG)2CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 8 29 1/8
LY-2 19.9 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 9/10
   (CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 1/10
R27 19.4 (CAG) 3 CAA(CAG) 9 (CAACAG) 3 (CAACAGCAG) 2 CAA 1 26 8/9
   (CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/9
MDA-MB435 1.3 (CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA 10 29 2/8
   (CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 3/8
   (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 1 26 2/8
   (CAG)6CAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA 11 26 1/8
LCC6 2.0 (CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)2(CAACAGCAG)2CAA 12 28 1/9
   (CAG)3CAA(CAG)2CAA(CAG)6(CAACAG)3(CAACAGCAG)2CAA 13 26 1/9
   (CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 3/9
   (CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)3(CAACAGCAG)2CAA 14 30 1/9
   (CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 15 28 1/9
   (CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA 10 29 1/9
   (CAG)3CAA(CAG)2CAACAGCAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA 16 28 1/9
ZR-75-1 1.5 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 6/7
   (CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 3 28 1/7
AK-47 1.4 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 2/8
   (CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 11 28 5/8
   (CAG)5CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 15 27 1/8
A1N4 2.0 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 20/41
   (CAG)4CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 17 27 21/41
  1. aLCC1: estrogen independent and responsive which is selected for growth in vivo without estrogens; LCC2: selected from LCC1 by treatment with 4-OH TAM; LCC9: selected from LCC1 by treatment with ICI 182780, resistant to ICI182780 and 4-OH TAM:, LY-2: selected for resistance to 4-OH TAM, KEO and LY 117018; R27: able to grow in the presence of 4-OH TAM. LCC6 is the more aggressive variant of MD-MB435. AK-47 is the variant derived from ZR-75-1. A1N4 is a normal breast cell line. The parental sequence patterns are in bold.